The Pathwork® Tissue Of Origin Test: Received FDA Clearance
August 1, 2008 by Gloria Gamat
Filed under Diseases & Conditions
Pathwork Diagnostics, Inc. recently announced that its Pathwork® Tissue of Origin Test for use in hard-to-identify-tumors has been cleared by the FDA.
The test analyzes a tumor’s gene expression pattern to help pinpoint the source of hard-to-identify tumors and is the first test of its kind to receive FDA clearance.
Up to an estimated 200,000 newly diagnosed cancer patients annually in the U.S. may have a tumor for which the site of origin is uncertain after the initial diagnostic workup.
The FDA’s clearance underscores the growing role that patients’ genomic information can play in helping physicians make better decisions.
Read the full press release from Pathwork Diagnostics, Inc. (pdf file)
I find this test extremely interesting. The more doctors are able to learn about patients’ tumors the more likely that they will be able to help them.
yes it is. if this test is readily available (read: affordable) to all cancer patients, this will help make the best course of treatment.